Tamiflu Reduced Risk of Death by 25% in Patients Hospitalised with H1N1

A meta-analysis published online today in The Lancet Respiratory Medicine has concluded that patients admitted to hospital with H1N1 influenza during the 2009/2010 pandemic were 25% less likely to die from the disease if they had been given neuraminidase inhibitors (NAIs) such as Roche’s Tamilfu. Until now, [Governments] had no adequate data to assist them in deciding if lives were saved in 2009-2010 …

Presentation download: Successful development of H1N1 vaccine in partnership with key industry stakeholders

The National Health Research Institutes (NHRI) is a non-profit foundation established by the Taiwanese government in 1996. The main objective of the institute is to the enhance  medical research and the improvement of health care in Taiwan. At World Vaccine Congress Asia this year, we had the privileged to have Dr. Pele Chong, Investigator & Director Vaccine Research & Development …

Asia’s role in the global vaccine industry

At World Vaccine Congress Asia last June, Patrick Bergstedt, President, Asia Pacific of MSD, Labeeb Abboud, General Counsel & SVP Business Development of International AIDS Vaccine Initiative and Stanley Chang, Chairman & Chief Executive Officer of Medigen came together to discuss how Asia can play a role for the global vaccine industry. The discussion centered around the need for closer …

#wvcusa Dr Ellen Vigdorth from @Quintiles discussing climate change in #vaccine trials

Vaccine trials: Today at the World Vaccine Congress, Dr Ellen Vigdorth presented about the critical role of epidemiology, temporal requirements and local customs integration into design, planning and delivery for successful vaccine trials. Historically, clinical trials in North America and Europe were very organized, according to Dr. Virgdorth.  Now, as many studies have moved into the Southern hemisphere and Asia, …

Climate change in vaccine trials: Moving from a one-size-fits-all to a custom fit in operational delivery

Dr Vigdorth has 30 years of drug development research experience in the clinical setting and pharmaceutical and CRO industries. She has led clinical development programs across a range of therapeutic indications with extensive experience in antibiotic, antiviral, vaccine, and antifungal agents.   Dr Vigdorth's experience has developed from multiple perspectives including working in the clinical investigative site setting, multi- national …